PFIZER INC.

PFIZER INC. filed a Q2 report for PFIZER INC. on July 21, 2025.

Lobbying for PFIZER INC.

All filings by PFIZER INC. · Everything PFIZER INC. has reported

Amended

The filer submitted a later report covering this same period, so the amounts here have been replaced. Site totals count only the latest version. See the current filing, posted Oct 20, 2025.

Filing · LD-2 quarterly report Q2 report

Reporting period

2nd Quarter 2025

Apr 1 - June 30 · Posted Jul 21, 2025

Expenses

$3,490,000

What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

District of Columbia

Official filing document

Government bodies contacted 10

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 5

Budget/Appropriations

HR 1 - One Big Beautiful Bill Act CDC Reform Vaccine Policy Reconciliation Research & Development

Health Issues

S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 832 - EPIC Act of 2025 HR 1 - One Big Beautiful Bill Act CDC Reform Vaccine Policy Reconciliation Research & Development HR 946 - ORPHAN Cures Act HR 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program HR 2214 - DRUG Act HR 2450 - Prescription Drug Transparency and Affordability Act PL 117-328 Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Biosimilars Access, Reimbursement and Reform 340B Reform Prescription Drug User Fee Act (PDUFA) Inflation Reduction Act (IRA) Pill Penalty Vaccine Coverage and Access Intellectual Property Protections PBM Reform Cancer Policies Drug Pricing

Medicare/Medicaid

S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 832 - EPIC Act of 2025 HR 946 - ORPHAN Cures Act HR 2450 - Prescription Drug Transparency and Affordability Act Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients PBM Reform Medicaid Prescription Drug Access Digital Therapeutics

Taxation/Internal Revenue Code

VICP Reform and Excise Tax Vaccine Injury Compensation Program

Trade (domestic/foreign)

International Supply Chain Global Access Tariffs Non-Tariff Trade Barriers

Bills named in this filing 5

H.R. 1
One Big Beautiful Bill Act
H.R. 946
ORPHAN Cures Act
H.R. 1492
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…
H.R. 2214
DRUG Act
H.R. 2450
Prescription Drug Transparency and Affordability Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.